Pulmonary arterial hypertension (PAH) is a serious condition in which the small arteries in your lungs become narrowed and stiff, forcing the right side of your heart to work much harder to push blood through. It’s defined by a mean pressure in the pulmonary arteries above 20 mmHg, measured during a procedure called right heart catheterization. PAH is rare, affecting roughly 15 people per million, but it’s progressive and can lead to right heart failure if untreated.
How PAH Differs From Other Pulmonary Hypertension
Pulmonary hypertension is a broad term covering any condition where blood pressure in the lung arteries is too high. The World Health Organization divides it into five groups based on the underlying cause. PAH is Group 1, and it stands apart because the problem originates in the lung arteries themselves rather than being a consequence of another condition.
The other groups include pulmonary hypertension caused by left heart disease (the most common type overall), chronic lung diseases like COPD or interstitial lung disease, blood clots that block the pulmonary arteries, and a final category of rare or overlapping conditions. Treatment differs significantly between groups, which is why pinpointing the correct classification matters so much.
Within Group 1, PAH can be idiopathic (no identifiable cause), heritable (linked to genetic mutations), or associated with other conditions like connective tissue diseases, HIV infection, congenital heart defects, or liver disease. Certain drugs and toxins can also trigger it.
What Happens Inside the Lungs
PAH begins with dysfunction in the cells lining the pulmonary arteries. These cells normally produce substances that keep blood vessels relaxed and open. In PAH, the balance tips: production of natural vasodilators like nitric oxide and prostacyclin drops, while levels of a potent vessel-constricting substance called endothelin-1 rise. The result is chronic tightening of the arteries.
Vasoconstriction is likely the earliest step, but the disease doesn’t stop there. Over time, all three layers of the artery wall undergo remodeling. Cells proliferate, the walls thicken, and the structural scaffolding around the vessels breaks down and reorganizes abnormally. Small blood clots can form inside these damaged vessels, narrowing them further. The combined effect is a dramatic increase in the resistance blood encounters as it flows through the lungs, which places an ever-growing burden on the right ventricle of the heart.
Symptoms and How They Progress
Early PAH is easy to miss. The first symptom is usually shortness of breath during physical activity, something many people chalk up to being out of shape or getting older. As the disease advances, breathlessness starts showing up during lighter activities and eventually at rest.
Other symptoms include:
- Fatigue and weakness
- Chest pain, especially during exertion
- Dizziness or fainting spells
- A dry cough, sometimes producing blood
- Swelling in the legs, ankles, or abdomen
- Hoarseness or wheezing
Swelling in the lower body and abdomen signals that the right side of the heart is struggling to keep up, allowing fluid to back up in the veins. By the time these signs appear, the disease has typically progressed beyond its earliest stages.
How PAH Is Diagnosed
Because the symptoms overlap with many common conditions, PAH often takes months or years to diagnose. The process typically starts with noninvasive tests: an echocardiogram to estimate pressures in the heart, lung function tests, blood work, and a six-minute walk test to gauge exercise capacity.
The definitive diagnosis requires right heart catheterization, which remains the gold standard. During this procedure, a thin catheter is threaded through a vein into the right side of the heart and into the pulmonary artery. It directly measures the pressures and resistance that define the condition. For a PAH diagnosis, the mean pulmonary artery pressure must be above 20 mmHg, the wedge pressure (reflecting left heart function) must be 15 mmHg or below, and pulmonary vascular resistance must be at least 3 Wood units. Getting these measurements right is critical. Errors in reading the wedge pressure, for instance, can lead to misclassification and inappropriate treatment.
The Role of Genetics
A significant minority of PAH cases have a genetic component. Mutations in a gene called BMPR2 account for 75% to 80% of heritable PAH cases. Among people diagnosed with PAH who have no family history of the disease, BMPR2 mutations are still found in roughly 11% to 40% of cases, depending on the population studied. A large French registry placed the figure at about 15%.
Having a BMPR2 mutation doesn’t guarantee you’ll develop PAH. The mutation reduces the body’s ability to keep cell growth in check within the pulmonary arteries, but other genetic and environmental factors influence whether the disease actually appears. Genetic counseling is often recommended for family members of people with heritable PAH.
Treatment Approaches
PAH has no cure, but treatments have improved considerably. Before 2024, medications targeted three main biological pathways. One group of drugs boosts the prostacyclin pathway, which helps relax blood vessels and prevent clotting. Another stimulates the nitric oxide pathway, keeping vessels dilated. The third blocks the effects of endothelin, the substance that constricts pulmonary arteries. Many patients end up on combination therapy targeting two or even all three pathways simultaneously.
In March 2024, the FDA approved sotatercept, the first drug in an entirely new class. Rather than relaxing blood vessels, sotatercept addresses the underlying remodeling process. It works as a molecular decoy, intercepting signals that drive excessive cell growth in the artery walls. By rebalancing these growth signals, it helps slow the thickening and stiffening that narrows the vessels in the first place. In clinical trials, it improved exercise capacity and disease markers when added to existing medications. It’s given as a subcutaneous injection and is currently approved as add-on therapy for patients with moderate symptoms, not as a standalone first treatment.
Survival and Risk Stratification
Prognosis depends heavily on how the disease responds to treatment and how quickly it’s caught. Doctors use risk stratification tools that combine exercise capacity, heart function markers, and other clinical measures to sort patients into low, intermediate, and high-risk categories.
Data from a multicenter study found that patients classified as low-risk after initial treatment had 100% survival at five years, with no deaths recorded during the follow-up period. Intermediate-risk patients had a five-year survival rate of about 66%. High-risk patients fare significantly worse. These numbers underscore why early diagnosis and aggressive treatment matter: moving from a higher risk category to a lower one through therapy translates directly into longer survival.
Living With PAH
Supervised exercise, once thought to be risky for PAH patients, is now generally encouraged in a structured, carefully monitored setting. Staying physically active within your limits helps maintain cardiovascular fitness and quality of life, though the intensity needs to be tailored to your functional status.
Pregnancy carries extreme risk for women with PAH. Maternal mortality rates in published data range from 30% to 56%, and medical guidelines strongly recommend against pregnancy. The physiological demands of pregnancy, particularly the massive increase in blood volume and cardiac output, can overwhelm a right ventricle already under strain. Women of childbearing age diagnosed with PAH need reliable contraception and thorough counseling about these risks.
High-altitude travel and exposure to low-oxygen environments can also worsen symptoms, since lower oxygen levels cause pulmonary arteries to constrict further. Planning ahead for air travel or visits to mountainous areas, including discussing supplemental oxygen with your care team, is a practical step that can prevent dangerous flare-ups.